Peter Rhode
Chief Tech/Sci/R&D Officer bei HCW BIOLOGICS INC.
Vermögen: 135 625 $ am 31.03.2024
Profil
Peter R.
Rhode was the founder of Sunol Molecular Corp.
founded in 1996, where he held the position of Research Director until 2002.
Currently, he is the Chief Scientific Officer & VP-Clinical Operations at HCW Biologics Inc. since 2019.
Previously, he worked as a Senior Scientist at Baxter International, Inc. from 1991 to 1996 and as Senior Vice President-Research & Development at Altor BioScience Corp.
from 2002 to 2019.
Dr. Rhode holds a doctorate degree from the University of Wisconsin and an undergraduate degree from the University of California, Davis.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
HCW BIOLOGICS, INC.
0,22% | 11.12.2023 | 77 500 ( 0,22% ) | 135 625 $ | 31.03.2024 |
Aktive Positionen von Peter Rhode
| Unternehmen | Position | Beginn |
|---|---|---|
| HCW BIOLOGICS INC. | Chief Tech/Sci/R&D Officer | 01.05.2019 |
Ehemalige bekannte Positionen von Peter Rhode
| Unternehmen | Position | Ende |
|---|---|---|
Altor BioScience Corp.
 Altor BioScience Corp. Pharmaceuticals: MajorHealth Technology Altor BioScience Corp. operates as a biopharmaceutical company which develops therapeutic products for the treatment of cancer. Its product candidates include ALT-801, a T-cell receptor-targeted immunotherapeutic for cancer and ALT-836, a monoclonal antibody-based tissue factor antagonist treatment of patients with acute respiratory distress syndrome and acute lung injury. The company was founded by Hing C. Wong in 2002 and is headquartered in Miramar, FL. | Chief Tech/Sci/R&D Officer | 01.01.2019 |
Sunol Molecular Corp.
 Sunol Molecular Corp. Pharmaceuticals: MajorHealth Technology Part of ImmunityBio, Inc., Sunol Molecular Corp. is a private company that develops gel therapeutics to treat disorders associated with the human tissue factor. The company is based in Miramar, FL. The company was founded by Hing C. Wong, Jon Weidanz, Peter R. Rhode. Sunol Molecular was acquired by Altor BioScience Corp., part of ImmunityBio, Inc. from August 01, 2017 on March 25, 2005. | Founder | 01.01.2002 |
| BAXTER INTERNATIONAL INC. | Corporate Officer/Principal | 01.01.1996 |
Ausbildung von Peter Rhode
| University of Wisconsin | Doctorate Degree |
| University of California, Davis | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BAXTER INTERNATIONAL INC. | Health Technology |
| HCW BIOLOGICS INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Altor BioScience Corp.
Altor BioScience Corp. Pharmaceuticals: MajorHealth Technology Altor BioScience Corp. operates as a biopharmaceutical company which develops therapeutic products for the treatment of cancer. Its product candidates include ALT-801, a T-cell receptor-targeted immunotherapeutic for cancer and ALT-836, a monoclonal antibody-based tissue factor antagonist treatment of patients with acute respiratory distress syndrome and acute lung injury. The company was founded by Hing C. Wong in 2002 and is headquartered in Miramar, FL. | Health Technology |
Sunol Molecular Corp.
Sunol Molecular Corp. Pharmaceuticals: MajorHealth Technology Part of ImmunityBio, Inc., Sunol Molecular Corp. is a private company that develops gel therapeutics to treat disorders associated with the human tissue factor. The company is based in Miramar, FL. The company was founded by Hing C. Wong, Jon Weidanz, Peter R. Rhode. Sunol Molecular was acquired by Altor BioScience Corp., part of ImmunityBio, Inc. from August 01, 2017 on March 25, 2005. | Health Technology |
